Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in
combination gemcitabine, in patients with eligible advanced solid tumors, determine the
maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a
recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics
(PK) and assess anti-tumor activity.